CSL Limited shares (ASX: CSL) fell to A$128.68 on Wednesday, marking a nine-year low, as markets continued to sell shares ...
CSL Limited (ASX:CSL), Australia’s leading biopharmaceutical company, has released its first Corporate Responsibility Report, combining information about the Company’s economic, social and ...
CSL shares hit a 9-year low as new demand concerns emerge. The post CSL's collapse deepens. Why this ASX giant can't find a ...
The Health Care (XHJ) industry slipped 6.01% to close at 26184.9. CSL Ltd closed $55.43 below its 52-week high ($184.62), which the company achieved on Tuesday, January 27. Trading volume of 2.4 ...
CSL ( (AU:CSL)) has shared an update. CSL Limited has provided an updated notification to the ASX on the progress of its on-market share buy-back program covering its ordinary fully paid shares. The ...
CSL ( (AU:CSL)) has provided an update. CSL Limited has reported the latest daily progress of its on-market share buy-back program for its ordinary fully paid shares. The company disclosed that it has ...
NEW YORK--(BUSINESS WIRE)-- Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited (CSLLY). CSL Limited is a ...
After a sharp decline, CSL is in a new phase. The question is what happens next. The post How much would $10,000 become if ...
Australia’s largest drugmaker CSL Ltd. is committing roughly $1.5 billion to expand its US manufacturing footprint, joining a wave of pharmaceutical giants doubling down on American production. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results